REG - Poolbeg Pharma PLC - Significant POLB 001 Patent Granted in USA

Poolbeg PharmaAnnouncement

01/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240501:nRSA6933Ma&default-theme=true

RNS Number : 6933M  Poolbeg Pharma PLC  01 May 2024

Poolbeg Pharma plc

 

Significant POLB 001 Patent Granted in United States

Immunomodulator II patent grant further strengthens robust intellectual
property portfolio for partnering

 

1 May 2024- Poolbeg Pharma (http://www.poolbegpharma.com/)  (AIM: POLB,
OTCQB: POLBF, 'Poolbeg' or the 'Company'), a biopharmaceutical company
focussed on the development and commercialisation of innovative medicines
targeting diseases with a high unmet medical need, announces that, further to
its announcement on 20 March 2024
(https://polaris.brighterir.com/public/poolbeg_pharma/news/rns/story/xq8d87x)
, the Company has received the fully granted patent from the US Patent Office
for its Immunomodulator II patent application.

 

The claims cover a class of drugs (including POLB 001) for treating
hypercytokinaemia (cytokine storm) and for preventing hypercytokinaemia in a
patient after an immune response has been triggered. This encompasses cytokine
storm that is induced in any disease indication. This further strengthens the
Company's robust intellectual property portfolio for POLB 001, thereby
enhancing the value and attractiveness of POLB 001 to potential Pharma
partners.

 

Poolbeg is actively building a comprehensive and worldwide IP portfolio, with
patents in place covering p38 MAP kinase inhibitors for the treatment of
severe influenza; and covering POLB 001 for the treatment of
hypercytokinaemia. Further patent applications have been filed and have
complementary coverage as the Company continues to expand its patent portfolio
covering POLB 001 and the wider class of p38 MAP kinase inhibitors,
particularly in respect of the treatment of cytokine release syndrome
following cancer immunotherapy.

 

Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma,
commented: "The grant received from the US Patent Office highlights the
strong progress we continue to make in developing and strengthening our patent
portfolio for POLB 001, across multiple disease indications. This further
enhances the value and attractiveness of POLB 001 for potential partners.

 

"We believe POLB 001 holds immense promise in addressing unmet medical needs
in cancer immunotherapy-induced cytokine release syndrome (CRS) and severe
influenza, positively impacting patients and healthcare systems alike. Its
impressive data package and strong patent portfolio, coupled with the
promising >US$10 billion market opportunity in cancer immunotherapy-induced
CRS alone, strengthens our confidence in its potential to positively impact
global health and generate value for our shareholders."

 

Enquiries

 

 Poolbeg Pharma Plc                                                               +44 (0) 207 183 1499

 Jeremy Skillington, CEO

 Ian O'Connell, CFO

  
 Cavendish Capital Markets Ltd (Nominated Adviser & Joint Broker)                 +44 (0) 207 220 0500

 Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM)

  
 Shore Capital Stockbrokers Ltd (Joint Broker)                                    +44 (0) 207 408 4090

 David Coaten, Harry Davies-Ball (Corporate Advisory), Malachy McEntyre, Isobel
 Jones (Corporate Broking)

 J&E Davy (Joint Broker)                                                          +353 (0) 1 679 6363

 Anthony Farrell, Niall Gilchrist

  
 Optimum Strategic Communications                                                 +44 (0) 208 078 4357

 Nick Bastin, Vici Rabbetts, Elena Bates                                          poolbeg@optimumcomms.com (mailto:poolbeg@optimumcomms.com)

  

 

About Poolbeg Pharma

 

Poolbeg Pharma plc is committed to the development and commercialisation of
innovative medicines targeting diseases with a high unmet medical need, with a
growing emphasis on rare and orphan diseases. Its model focusses upon
developing its exciting clinical assets and commercialising approved and
marketed drugs to support the growth of the Company and the development of its
robust pipeline of innovative products, thereby driving significant value
creation.

Poolbeg is led by an experienced leadership team with a history of delivering
significant shareholder value. The team has been strengthened by the
appointment of three former members of the Amryt Pharma plc leadership team,
with the intention of repeating Amryt's success and generating near term
revenues.

Poolbeg's clinical programmes target large addressable markets including
cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions
such as obesity with the development of an oral GLP-1R agonist. It uses a
cost-effective development philosophy to generate high quality human data to
support partnering and further development. Its AI-led infectious disease
programmes analyse unique data from human challenge trials to identify
clinically relevant drug targets and treatments, leading to faster development
and greater commercial appeal.

 

For more information, please go to www.poolbegpharma.com
(http://www.poolbegpharma.com/)  or follow us on Twitter
(https://twitter.com/PoolbegPharma)  and LinkedIn
(https://www.linkedin.com/company/poolbeg-pharma/)  @PoolbegPharma.

 

Forward-Looking Statements

This announcement may contain forward-looking statements and the words
"expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast",
"project" and similar expressions (or their negative) identify certain of
these forward-looking statements. The forward-looking statements in this
announcement are based on numerous assumptions and Poolbeg's present and
future business strategies and the environment in which Poolbeg expects to
operate in the future. Forward-looking statements involve inherent known and
unknown risks, uncertainties and contingencies because they relate to events
and depend on circumstances that may or may not occur in the future and may
cause the actual results, performance or achievements to be materially
different from those expressed or implied by such forward-looking statements.
These statements are not guarantees of future performance or the ability to
identify and consummate investments. Many of these risks and uncertainties
relate to factors that are beyond Poolbeg's ability to control or estimate
precisely, such as future market conditions, currency fluctuations, the
behaviour of other market participants, the outcome of clinical trials, the
actions of regulators and other factors such as Poolbeg's ability to obtain
financing, changes in the political, social and regulatory framework in which
Poolbeg operates or in economic, technological or consumer trends or
conditions. Past performance should not be taken as an indication or guarantee
of future results, and no representation or warranty, express or implied, is
made regarding future performance. No person is under any obligation to update
or keep current the information contained in this announcement or to provide
the recipient of it with access to any additional relevant information.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  REAIMMFTMTIJBAI